openPR Logo
Press release

Facioscapulohumeral Muscular Dystrophy Clinical Trials, Treatment Drugs, Pipeline Insights, and Companies 2024

09-26-2024 02:01 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Facioscapulohumeral Muscular Dystrophy Pipeline

Facioscapulohumeral Muscular Dystrophy Pipeline

DelveInsight's, "Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Facioscapulohumeral Muscular Dystrophy pipeline landscape. It covers the Facioscapulohumeral Muscular Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Facioscapulohumeral Muscular Dystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Facioscapulohumeral Muscular Dystrophy pipeline products in this space.

Discover the latest drugs and treatment options in the Facioscapulohumeral Muscular Dystrophy Pipeline. Dive into DelveInsight's comprehensive report today! @ Facioscapulohumeral Muscular Dystrophy Pipeline Outlook- https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Facioscapulohumeral Muscular Dystrophy Pipeline Report
• July 2024:- Hoffmann-La Roche- A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy.
• DelveInsight's Facioscapulohumeral Muscular Dystrophy pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Facioscapulohumeral Muscular Dystrophy treatment.
• The leading Facioscapulohumeral Muscular Dystrophy Companies such as Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Inc., Avidity Biosciences, Inc., and others.
• Promising Facioscapulohumeral Muscular Dystrophy Therapies such as Losmapimod, RO7204239, AOC 1020, and others.

Stay ahead with the most recent pipeline outlook for Facioscapulohumeral Muscular Dystrophy. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Facioscapulohumeral Muscular Dystrophy Treatment Drugs- https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Facioscapulohumeral Muscular Dystrophy Emerging Drugs Profile

• Losmapimod: Fulcrum Therapeutics
Losmapimod is an investigational, selective p38α/β mitogen activated protein kinase (MAPK) inhibitor. Fulcrum exclusively in-licensed losmapimod from GSK following Fulcrum's discovery of the role of p38α/β inhibitors in the reduction of DUX4 expression and an extensive review of known compounds. Results reported from the ReDUX4 trial demonstrated slowed disease progression and improved function, including positive impacts on upper extremity strength, supporting losmapimod's potential to be a transformative therapy for the treatment of FSHD. Although losmapimod had never previously been explored in muscular dystrophies, it had been evaluated in more than 3,600 subjects in clinical trials across multiple other indications, with no safety signals attributed to losmapimod.

• DYNE-301: Dyne Therapeutics
DYNE-301 is a DUX4L1 protein expression stimulant, which consists of company's proprietary Fab conjugated with our linker to an ASO that is designed to address the genetic basis of FSHD by reducing DUX4 expression in muscle tissue. Proof-of-concept data showing that DYNE-301 reduced expression of key DUX4 biomarkers in FSHD patient myotubes, a type of muscle cell. Currently the product is in preclinical stage of development for the disease.

Explore groundbreaking therapies and clinical trials in the Facioscapulohumeral Muscular Dystrophy Pipeline. Access DelveInsight's detailed report now! @ New Facioscapulohumeral Muscular Dystrophy Drugs- https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Facioscapulohumeral Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Facioscapulohumeral Muscular Dystrophy Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Unveil the future of Facioscapulohumeral Muscular Dystrophy Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Facioscapulohumeral Muscular Dystrophy Market Drivers and Barriers- https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Facioscapulohumeral Muscular Dystrophy Pipeline Report
• Coverage- Global
• Facioscapulohumeral Muscular Dystrophy Companies- Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Inc., Avidity Biosciences, Inc., and others.
• Facioscapulohumeral Muscular Dystrophy Therapies- Losmapimod, RO7204239, AOC 1020, and others.
• Facioscapulohumeral Muscular Dystrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Facioscapulohumeral Muscular Dystrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Facioscapulohumeral Muscular Dystrophy Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Facioscapulohumeral Muscular Dystrophy Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Facioscapulohumeral Muscular Dystrophy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Facioscapulohumeral Muscular Dystrophy- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Losmapimod: Fulcrum Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. DYNE-301: Dyne Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Facioscapulohumeral Muscular Dystrophy Key Companies
21. Facioscapulohumeral Muscular Dystrophy Key Products
22. Facioscapulohumeral Muscular Dystrophy- Unmet Needs
23. Facioscapulohumeral Muscular Dystrophy- Market Drivers and Barriers
24. Facioscapulohumeral Muscular Dystrophy- Future Perspectives and Conclusion
25. Facioscapulohumeral Muscular Dystrophy Analyst Views
26. Facioscapulohumeral Muscular Dystrophy Key Companies
27. Appendix

List of Top Selling Market Research Reports in 2024

Abdominal Aortic Aneurysm Market- https://www.delveinsight.com/report-store/abdominal-aortic-aneurysm-market
Acute Myeloid Leukemia Market- https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-market
Adult T-cell Leukemia Market- https://www.delveinsight.com/report-store/adult-t-cell-leukemia-lymphoma-market
Alcoholic Hepatitis Market- https://www.delveinsight.com/report-store/alcoholic-hepatitis-market
Beta Thalassemia Market- https://www.delveinsight.com/report-store/beta-thalassemia-market
Blastomycosis Market- https://www.delveinsight.com/report-store/blastomycosis-market
Carbapenem-resistant Enterobacteriaceae Infection Market- https://www.delveinsight.com/report-store/carbapenem-resistant-enterobacteriaceae-infection-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-syndrome-market
Central Retinal Vein Occlusion Market- https://www.delveinsight.com/report-store/central-retinal-vein-occlusion-market
Clostridium Difficile Infections Market- https://www.delveinsight.com/report-store/clostridium-difficile-infections-clostridium-difficile-associated-disease-market
Congenital Heart Defect Market- https://www.delveinsight.com/report-store/congenital-heart-defect-devices-market
Diabetic Gastroparesis Market- https://www.delveinsight.com/report-store/diabetic-gastroparesis-market-size
Familial Adenomatous Polyposis Market- https://www.delveinsight.com/report-store/familial-adenomatous-polyposis-market
Gastroparesis Market- https://www.delveinsight.com/report-store/gastroparesis-market
Genital Herpes Market- https://www.delveinsight.com/report-store/genital-herpes-market
Trauma Fixation Devices Market- https://www.delveinsight.com/report-store/trauma-devices-market
Vascular Imaging Devices Market- https://www.delveinsight.com/report-store/vascular-imaging-market-market
Venous Thromboembolism Market- https://www.delveinsight.com/report-store/venous-thromboembolism-market
Vulvar Cancer Market- https://www.delveinsight.com/report-store/vulvar-cancer-market
Brucellosis Market- https://www.delveinsight.com/report-store/brucellosis-market
Pacemakers Market- https://www.delveinsight.com/report-store/pacemakers-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Intraocular Lymphoma Market- https://www.delveinsight.com/report-store/intraocular-lymphoma-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market
Transcatheter Heart Valve Replacement Devices Market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
Endoscopic Ultrasound Market- https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Trichomoniasis Market- https://www.delveinsight.com/report-store/trichomoniasis-market-insights
Radiodermatitis Market- https://www.delveinsight.com/report-store/radiodermatitis-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
CXCR Inhibitors Market- https://www.delveinsight.com/report-store/c-x-c-chemokine-receptor-inhibitors-competitive-landscape-market-and-pipeline-analysis
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Pigment Epithelial Detachment Market- https://www.delveinsight.com/report-store/pigment-epithelial-detachment-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
UK Healthcare Report- https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
Surgical Energy Generators Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Surgical Sealant Tissue Patch Market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Surgical Stapling Devices Market- https://www.delveinsight.com/report-store/surgical-stapling-devices-market
Vital Sign Monitoring Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Syphilis Market- https://www.delveinsight.com/report-store/syphilis-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Pelvic Organ Prolapse Market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
SGLT2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Urinary Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-syndrome-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Lymphedema Market- https://www.delveinsight.com/report-store/lymphedema-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Overactive Bladder Market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Facial Lines Market- https://www.delveinsight.com/report-store/facial-lines-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
+91-9650213330

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Facioscapulohumeral Muscular Dystrophy Clinical Trials, Treatment Drugs, Pipeline Insights, and Companies 2024 here

News-ID: 3669219 • Views:

More Releases from DelveInsight Business Research LLP

Myopia Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024
Myopia Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024
DelveInsight's, "Myopia Pipeline Insight 2024" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Myopia pipeline landscape. It covers the Myopia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myopia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Myopia
Severe Hypertriglyceridemia Treatment Drugs, Pipeline Insights, Emerging Therapies and Companies 2024
Severe Hypertriglyceridemia Treatment Drugs, Pipeline Insights, Emerging Therapi …
DelveInsight's, "Severe Hypertriglyceridemia Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Severe Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Severe
Melanoma Pipeline Outlook, Emerging Therapies, Clinical Trials, and Companies 2024
Melanoma Pipeline Outlook, Emerging Therapies, Clinical Trials, and Companies 20 …
DelveInsight's, "Melanoma Pipeline Insight 2024" report provides comprehensive insights about 150+ companies and 170+ pipeline drugs in Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Melanoma Pipeline Report In September 2024:- Iovance Biotherapeutics Inc.- This
Major Depressive Disorder Pipeline Outlook, Emerging Drugs, and Companies 2024
Major Depressive Disorder Pipeline Outlook, Emerging Drugs, and Companies 2024
DelveInsight, "Major Depressive Disorder Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Major Depressive Disorder pipeline landscape. It covers the Major Depressive Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Major Depressive Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover

All 5 Releases


More Releases for Facioscapulohumeral

Australia boosts gene disease detection capacity
New technology detects genetic diseases previously unable to be identified World leading technology in identifying disease genes has arrived in Australia to facilitate new diagnostic genomic tests for patients with life affecting genetic conditions. Funded by philanthropy through FSHD Global Research Foundation, Australia's only funding body for the debilitating condition, Facioscapulohumeral muscular dystrophy (FSHD), the technology will provide answers for patients who have been previously mis-diagnosed or who have been unable
Facioscapulohumeral Muscular Dystrophy (FSHD) Pipeline Assessment | Insights int …
Currently, there are no specific therapeutic cures for Facioscapulohumeral Muscular Dystrophy (FSHD). But in 2010, the standard of care and management of FSHD were discussed, and a census was agreed on at the 171st ENMC International Workshop. The main treatment strategies are divided upon the different aspects of the muscle systems it affects. Globally, several prominent pharma companies are actively working on developing therapies for Facioscapulohumeral Muscular Dystrophy. The launch of
Muscular Dystrophy Treatment Market Demand is Increasing in Most Part of World 2 …
Muscular Dystrophy is characterized by a collection of muscle-wasting conditions. The disorder is caused by genetic mutations which interfere with the production of muscle protein dystrophin, necessary to build muscles. Muscular dystrophy is a genetic disease, consequently, the chance of an individual developing a disease increases with a history of muscular dystrophy in the family. The symptoms include shortening of muscles and tendons, the curvature of spine, weakening of heart
Muscular Dystrophy Treatment Market Opportunity Analysis, 2018–2026
Muscular Dystrophy is characterized by a collection of muscle-wasting conditions. The disorder is caused by genetic mutations which interfere with the production of muscle protein dystrophin, necessary to build muscles. Muscular dystrophy is a genetic disease, consequently, the chance of an individual developing a disease increases with a history of muscular dystrophy in the family. The symptoms include shortening of muscles and tendons, the curvature of spine, weakening of heart
Muscular Dystrophy Treatment Market to Witness Robust Expansion by 2026
Muscular Dystrophy is characterized by a collection of muscle-wasting conditions. The disorder is caused by genetic mutations which interfere with the production of muscle protein dystrophin, necessary to build muscles. Muscular dystrophy is a genetic disease, consequently, the chance of an individual developing a disease increases with a history of muscular dystrophy in the family. The symptoms include shortening of muscles and tendons, the curvature of spine, weakening of heart
Muscular Dystrophy Treatment Market - Global Industry Insights, Trends, Outlook, …
Muscular Dystrophy is characterized by a collection of muscle-wasting conditions. The disorder is caused by genetic mutations which interfere with the production of muscle protein dystrophin, necessary to build muscles. Muscular dystrophy is a genetic disease, consequently, the chance of an individual developing a disease increases with a history of muscular dystrophy in the family. The symptoms include shortening of muscles and tendons, the curvature of spine, weakening of heart